Asensus Surgical (NYSE:ASXC) shares slid today on fourth-quarter results that missed the consensus sales forecast.
The Research Triangle Park, North Carolina-based surgical robotics company posted losses of $15.9 million, or 7¢ per share, on sales of $2.1 million for the three months ended Dec. 31, 2021, for a slight bottom-line further into the red despite sales numbers that were more than tripled from this period a year ago.
Adjusted to exclude one-time items, losses per share were also 7¢, falling even with projections on Wall Street, where analysts were looking for sales of $1.5 million
Asensus Surgical President and CEO Anthony Fernando said in a news release that, despite headwinds throughout 2021, the company — formerly known as TransEnterix — grew its active installed base and produced the highest procedure volumes in the Senhance surgical robot’s commercial history.
“As we look towards 2022, we expect to continue to drive the global…